Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ · Healthcare
Monte Rosa Therapeutics, Inc. Income Statement 2023–2025
| Dec 2025 | Dec 2024 | Dec 2023 | |
|---|---|---|---|
| Revenues | |||
| Revenue | 123.7M | 75.6M | 0 |
| Gross Profit | — | — | — |
| Profitability | |||
| Operating Income | -54.2M | -81.1M | -143.3M |
| EBITDA | — | — | — |
| Net Income | -38.6M | -72.7M | -135.4M |
| Per Share Data | |||
| EPS (diluted) | — | — | — |
| Shares Outstanding (dil.) | 83M | 74M | 51M |
Monte Rosa Therapeutics, Inc. Income Statement — FAQ
Monte Rosa Therapeutics, Inc. (GLUE) income statement over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see GLUE's income statement history?
The chart and table above show Monte Rosa Therapeutics, Inc.'s income statement by year and by quarter, including the growth rate.